The paper's citation list
No.The paper's citation list
1Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018;50: doi: 10.1038/s12276-018-0115-0
2Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019;90:138 doi: 10.1007/s00115-018-0571-8
3Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019;9: doi: 10.3389/fonc.2019.00396
4Current Applications for Overcoming Resistance to Targeted Therapies. 2019;20:97 doi: 10.1007/978-3-030-21477-7_4
5Recent advances in localized immunotherapy of skin cancers. 2019;11:443 doi: 10.2217/imt-2018-0139
6CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. 2018;6:105 doi: 10.3390/biomedicines6040105
7Bioactive Nanoparticles for Cancer Immunotherapy. 2018;19:3877 doi: 10.3390/ijms19123877
8MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. 2019;303:223 doi: 10.1016/j.jconrel.2019.04.019
9Learning-accelerated discovery of immune-tumour interactions. 2019;4:747 doi: 10.1039/C9ME00036D
10Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. 2019; doi: 10.1007/s40883-019-00113-6
11Checkpoint inhibitors: What gastroenterologists need to know. 2018;24:5433 doi: 10.3748/wjg.v24.i48.5433
12Resistance to Targeted Therapies in Lymphomas. 2019;21:155 doi: 10.1007/978-3-030-24424-8_7
13Cancer and the Immune System: The History and Background of Immunotherapy. 2019;150923 doi: 10.1016/j.soncn.2019.08.002
14Editorial. 2019;12:3 doi: 10.1111/ors.12402
15Molecular and Cell Biology of Cancer. 2019;117 doi: 10.1007/978-3-030-11812-9_7
16Combined strategies for tumor immunotherapy with nanoparticles. 2019; doi: 10.1007/s12094-019-02081-3
17Novel therapeutic strategies for spinal osteosarcomas. 2019; doi: 10.1016/j.semcancer.2019.05.018
18The emergence of drug resistance to targeted therapies: Clinical evidence. 2019;100646 doi: 10.1016/j.drup.2019.100646
19Nanoparticles: Properties and Applications in Cancer Immunotherapy. 2019;25:1962 doi: 10.2174/1381612825666190708214240
20Immunotherapy. 2018;995:131 doi: 10.1007/978-3-030-02505-2_6